Focus Partners Wealth
CTKB icon

Focus Partners Wealth’s Cytek Biosciences CTKB Stock Holding History

Focus Partners Wealth’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$147K Buy
33,677
+180
+0.5% +$850 ﹤0.01% 2465
2025
Q4 		$169K Sell
33,497
-37,079
-53% -$172K ﹤0.01% 2474
2025
Q3 		$31.2M Buy
+70,576
New +$265K 0.05% 299

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Focus Partners Wealth's CTKB Position: Q1 2026 in Review

Focus Partners Wealth increased its Cytek Biosciences (CTKB) stake by 0.54% in Q1 2026, buying an estimated $850 and bringing the position to 33,677 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #2465.

Focus Partners Wealth first reported a position in CTKB in Q3 2025 and has held it in 3 quarters since. The position peaked at $31.2M in Q3 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Focus Partners Wealth held 33,677 shares of Cytek Biosciences worth $147K as of Q1 2026.
  • Focus Partners Wealth bought 180 Cytek Biosciences shares in Q1 2026, an estimated $850.
  • Cytek Biosciences made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2465 holding.
  • Focus Partners Wealth first reported a position in Cytek Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Focus Partners Wealth's Cytek Biosciences position peaked at $31.2M in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.